Randomized and Multicenter Study to Evaluate a Customizable Support Breast Cancer Material

Breast Cancer Clinical Trial

Official title:

Randomized and Multicenter Study to Evaluate the Impact of a Customizable Support Material in the Knowledge and Satisfaction of Breast Cancer Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05798312
• Other study ID #: IMAP-CM
• Status: Completed
• Phase: N/A
• Start date: May 21, 2021
• Est. completion date: March 13, 2022

Study information

• Verified date: April 2023
• Source: Medicos e Investigadores en la Lucha contra el Cancer de Mama
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to evaluate if a customizable support material allows to improve the knowledge about the stage and subtype of the disease, as well as the indicated treatments, in comparison with a non-customizable support material among patients with breast cancer. The main question it aims to answer is: • What is the impact of delivering a customizable support material so that patients with breast cancer know and remember the stage and subtype of their disease, as well as the indicated treatments, compared to non-customizable support material? Participants in the intervention group will be provided customizable support material while those in the standard group will receive a non-customizable material.

Description:

In the present investigation, it is planned to carry out a prospective, multicenter study, randomized and blinded to the statistician. Patients with a recent diagnosis of CM and who are scheduled to have their first consultation in which their options will be discussed of treatment to participate in the study. To those who agree to participate and sign the informed consent, the protocol coordinator of each center will randomly assign them to the intervention group or the standard group (in a 1:1 ratio) before the appointment medical. The intervention group will receive customizable support material while the Standard group will receive a non-customizable material (Annex 2). Additionally, you will be instructed to the intervention group that the support material received can be filled with the information discussed with the medical team. The protocol coordinator will obtain sociodemographic data and clinicopathology of the medical records of the participants. After the next visit follow-up, the coordinator will apply to both groups questionnaires about the knowledge of the patient about his own disease, satisfaction with the support material received and perceived ability to participate in discussions about their treatment, and the comprehension of written materials (CHLT-6). After one month, both groups will respond knowledge questionnaires to assess long-term information retention, disease uncertainty (SF-MUIS) and satisfaction with medical information provided (EORTC-QLQ-INFO25).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 125
• Est. completion date: March 13, 2022
• Est. primary completion date: March 13, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Women with a recent diagnosis of primary breast cancer treated at the participant centers
• Women who will receive information about their options for the first time treatment
• Provision of informed consent to participate in the study

Exclusion Criteria:

• Patients who have already started systemic treatment for breast cancer
• Patients with medical records not available for data collection

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Knowledge, Attitudes, Practice
• Patient Empowerment
• Patient Satisfaction

Intervention

Other:
• Customizable support material
Customizable support material will enable patients to identify their personal breast cancer information.
• Non-customizable support material
Non-customizable support material will include general breast cancer information.

Locations

Country	Name	City	State
Mexico	Hospital Zambrano Hellion	San Pedro Garza Garcia	Nuevo Leon

Sponsors (2)

Lead Sponsor	Collaborator
Medicos e Investigadores en la Lucha contra el Cancer de Mama	Roche Pharma AG

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Knowledge	Evaluate if a customizable support material allows to improve the knowledge about the stage and subtype of the disease, as well as the indicated treatments, in comparison with a non-customizable support material as measured by the knowledge questionnaire assessing patients' knowledge of their disease extension (in situ vs invasive cancer); clinical stage; estrogen, progesterone and HER2 receptor status; and treatments to which they are candidates.	1-month
Secondary	Patient satisfaction	Assess patient satisfaction with the written information provided and the perception of their ability to actively participate in discussions about the treatment when offered a customizable educational brochure and compare it to the patients receiving a non-customizable brochure	1-month
Secondary	Comprehension	Determine if the comprehension of written materials (customizable or not customizable) is associated with the level of health literacy (Health Literacy) as measured by the Cancer Health Literacy Test - 6 (CHLT-6) instrument	1-month
Secondary	Satisfaction with medical information	To determine if satisfaction with medical information is higher when offered a customizable vs. non-customizable educational brochure as per measured by the European Organization for Research and Treatment of Cancer test Quality of Life Group information questionnaire (EORTC QLQ-INFO 25)	1-month
Secondary	Illness uncertainty	Determine if the uncertainty of the disease with the medical information is lower when offered a customizable educational brochure versus offering non-customizable material, as measured by the short form of Mishel Uncertainty Illness Scale (SF-MUIS)	1-month